There are 2789 resources available
248P - The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry
Presenter: Marissa Meegdes
Session: ePoster Display
249P - The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study
Presenter: Pierre-Olivier Graff
Session: ePoster Display
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display
252P - Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
Presenter: Claudia Noto
Session: ePoster Display
254P - Impact of palbociclib-dose reduction on survival: A retrospective cohort study
Presenter: Maria Luisa Romero Lagures
Session: ePoster Display
255P - Propreseer: A reliable, collaborative prognostic model for tamoxifen-resistance breast cancer
Presenter: Weiqi Nian
Session: ePoster Display
Resources:
Abstract
362P - Influence of the expression of ABCG2 transporters on the results of photodynamic therapy in malignant gliomas
Presenter: Artemii Rynda
Session: ePoster Display